Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107653
Status:
COMPLETED
Last Update Posted:
2016-06-21
First Post:
2005-04-06
Brief Title:
Latino Study - A Study of PEGASYS Peginterferon Alfa-2a 40KD and COPEGUS Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Prospective Multicenter Open-label Comparative Efficacy Study of Pegasys Plus Copegus in Treatment-naïve Latino Patients With Chronic Hepatitis C-genotype 1 as Compared to Treatment-naïve Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This single arm study will evaluate the efficacy and safety of PEGASYS 180 micrograms sc weekly plus ribavirin 1000-1200mg po daily in treatment-naive Latino patients versus non-Latino Caucasian patients with chronic hepatitis C- genotype 1 The anticipated time on study treatment is 3-12 months and the target sample size is 500 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None